Overweight, Obesity Remained Highly Prevalent in U.S. Youths in 2024
via HealthDayTUESDAY, Feb. 17, 2026 -- Excess youth overweight and obesity remained highly prevalent in the United States in 2024, according to a study published online Feb. 10 in JAMA Network Open.
William J. Heerman, M.D., M.P.H., from Vanderbilt University Medical Center in Nashville, Tennessee, and colleagues used electronic health records from the National Patient-Centered Clinical Research Network, which included eight clinical research networks, to provide updated estimates of youth overweight, obesity, and severe obesity.
Data were available for 6,094,825 youths across the United States, with broad geographic representation. The researchers found that 19.8 percent of youths aged 2 to 19 years had obesity. Overall, 26.9 percent of children aged 2 to 5 years had overweight or obesity, increasing to 38.5 percent at ages 12 to 19 years. Among adolescents and young adults, 9.2 percent had severe obesity. Among those aged 12 to 19 years, healthy weight was seen in 49.5, 52.3, 49.1, 47.3, and 59.3 percent of American Indian or Alaska Natives, Blacks, Hispanics, Native Hawaiian or Other Pacific Islanders, and Whites, respectively.
"These results demonstrate the uneven distribution of obesity and severe obesity across youths in the U.S. and underscore the need for ongoing treatment, prevention, and public health interventions to reduce excess adiposity in youths," the authors write.
One author disclosed ties to AstraZeneca.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2026-02-18 13:38
Read more
- FDA Expands Tater Tot Recall Tied to Possible Plastic Contamination
- Couples Who Do This One Thing Feel More Satisfied And Secure Together
- Risk Factors Associated With Child Food Allergy Identified
- Recommendations Developed for Primary Care Asthma Management in Veterans, Military Members
- FDA Approves Filkri (filgrastim-laha), a Biosimilar to Neupogen
- Disc Medicine Receives Complete Response Letter from FDA for Bitopertin for the Treatment of EPP
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions